Despite the use of smart pumps, intravenous medication errors still exist.
This indicates the need for a standardized method of measuring errors and highlights the importance of identifying issues related to the administration of smart pump medication in order to improve patient safety.
Objective we conducted a multi-site study to investigate the type and frequency of intravenous medication errors associated with smart pumps in the United States.
Methods 10 hospitals of different sizes from different suppliers were involved using smart pumps.
Data were collected using a forward-looking point prevalence approach to capture errors related to drugs taken through smart pumps and to assess their potential hazards.
Results a total of 478 patients and 1164 medication were evaluated.
In the observed infusion, 699 (60%)
One or more errors related to their management.
Errors found, such as labeling errors and bypassing smart pumps and drug depots, are primarily related to violations of hospital policies.
These types of errors can lead to medication errors.
According to the National Coordination Committee on Drug error reporting and prevention (NCC MERP).
Class 1 E error (0. 1%)
Class D 4 (0. 3%)
Class C 492 (
Excluding deviations from hospital policies)(42%)
Confirmed.
Among them, the most common mistakes are unauthorized drug treatment, bypass smart pumps, and error rates.
Conclusion despite the use of smart pumps, we found a high error rate for intravenous medication.
However, there are relatively few potentially harmful errors.
The results of this study will help to develop interventions to eliminate errors during intravenous medication.
Despite the use of smart pumps, intravenous medication errors still exist.
This indicates the need for a standardized method of measuring errors and highlights the importance of identifying issues related to the administration of smart pump medication in order to improve patient safety.
Objective we conducted a multi-site study to investigate the type and frequency of intravenous medication errors associated with smart pumps in the United States.
Methods 10 hospitals of different sizes from different suppliers were involved using smart pumps.
Data were collected using a forward-looking point prevalence approach to capture errors related to drugs taken through smart pumps and to assess their potential hazards.
Results a total of 478 patients and 1164 medication were evaluated.
In the observed infusion, 699 (60%)
One or more errors related to their management.
Errors found, such as labeling errors and bypassing smart pumps and drug depots, are primarily related to violations of hospital policies.
These types of errors can lead to medication errors.
According to the National Coordination Committee on Drug error reporting and prevention (NCC MERP).
Class 1 E error (0. 1%)
Class D 4 (0. 3%)
Class C 492 (
Excluding deviations from hospital policies)(42%)
Confirmed.
Among them, the most common mistakes are unauthorized drug treatment, bypass smart pumps, and error rates.
Conclusion despite the use of smart pumps, we found a high error rate for intravenous medication.
However, there are relatively few potentially harmful errors.
The results of this study will help to develop interventions to eliminate errors during intravenous medication.
Foot bottom contributors KOC, MS, CSY, SL and DWB: contributed to the concept and design of data and results, analysis and interpretation, drafting and writing of articles, for important knowledge content and final approval of the version to be released, it is subject to critical changes.
JA, DA, RC, CC, DLC, AD, LF, CAG-
P, MMH, RRM, NM, JM, SR, ER, DS, MDS, lp, KDS and EW: contributed analysis and interpretation of data and results to oversee data collection at each site, as well as drafting and writing of articles, for important knowledge content and final approval of the version to be released, make critical changes to it.
TWV: critical conception and revision of the paper for important intellectual content.
Fund the Carefusion Foundation;
Medical Device Promotion Association (AAMI).
No one declared a competitive interest.
Ethical approval partner of medical institution Review Committee.
Uncommissioned source and peer review;
External peer review.